Skip to main content

anti-cd20/anti-cd3/anti-cd8 trispecific antibody azd5492

Generic: Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492

anti-cd20/anti-cd3/anti-cd8 trispecific antibody azd5492: 2 clinical trials tracked.

anti-cd20/anti-cd3/anti-cd8 trispecific antibody azd5492 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-cd20/anti-cd3/anti-cd8 trispecific antibody azd5492, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trial Registry Records (2)

An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis

NCT06916806Registry updated 2026-09-15·Phase 1·AZN
Recruiting

Primary endpoint: Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events.

Interventionalopen72 targetStarted 2025-05Completion 2027-0937 sites · Canada, China, France, Germany…AstraZeneca

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)

NCT06542250Registry updated 2026-09-30·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: Frequency of dose limiting toxicities (DLTs).

Interventionalopen174 targetStarted 2024-09Completion 2029-1231 sites · Australia, Canada, China, Denmark…AstraZeneca